Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has over 11 commercial rare disease products: KHINDIVI, INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, HEMANGEOL, PKU GOLIKE, IMPAVIDO, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjectors. INCRELEX (mecasermin) is used to treat children who are very short for their age because their bodies do not make enough insulin-like growth factor-1 (IGF-1). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. NITISINONE is a prescription medicine used to treat adults and children with a hereditary disease called tyrosinemia type 1 (HT-1). The Company also has licensed United States rights to a rare disease product candidate ASN-001 (timolol topical gel).
Back to dashboard
Company Information
About this company
Key people
Norbert G. Riedel
Independent Chairman of the Board
Sean E. Brynjelsen
President, Chief Executive Officer, Director
Judith M. Matthews
Chief Financial Officer
Danka Radosavljevic
Chief Operating Officer
Ipek Erdogan-Trinkaus
Chief Commercial Officer
David C. Krempa
Chief Business Officer
Jennifer Adams
Independent Director
Charles J. Casamento
Independent Director
Paul V. Maier
Independent Director
Click to see more
Key facts
- Shares in issue28.58m
- EPICETON
- ISINUS29772L1089
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$1.63bn
- Employees44
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.